Preventing lung scarring may extend lives of lung cancer patientsOctober 30, 2007Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients - pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles. "The toxicity of pulmonary fibrosis limits the amount of the radiation dose that can be safely given to patients," said Simon Cheng, M.D., Ph.D., an author of the study and a radiation oncologist at New York University Medical Center in New York. "These study results may lead to more effective radiation therapies for advanced lung cancer, which is the leading cause of cancer deaths in the U.S." More than 50 percent of patients receiving radiation therapy for advanced lung cancer develop radiation-induced lung fibrosis, a painful side effect that can affect patients' quality of life and, in some cases, can be fatal. Pulmonary (lung) fibrosis involves inflammation and scarring of the lungs causing patients to feel short of breath, have a chronic dry cough, feel fatigue and pain in the chest, and suffer loss of appetite and weight loss. Over time, fibrosis causes the air sacs of the lungs to be replaced by scar tissue, causing difficulty breathing and an irreversible loss of the tissue's ability to transfer oxygen into the bloodstream.
This study involved mice treated with a 14 Gy single dose of radiation to the lungs. Researchers wanted to determine if using an antibody to block integrin beta6 (a specific activator of the transforming growth factor (TGF-beta) signaling pathway), could prevent the onset of radiation-induced pulmonary fibrosis. The study shows that mice that were given integrin beta6 monoclonal antibodies did not develop radiation-induced lung fibrosis, while the control group of mice developed the lung condition. "Fibrosis is a very serious side effect that often keeps doctors from giving patients a full dose of radiation for fear that the serious problems caused by fibrosis will outweigh the good done by the radiation. If further studies conclude that this drug can indeed prevent fibrosis in lung cancer patients, I believe researchers are a huge step closer to curing this disease," said Dr. Cheng. American Society for Therapeutic Radiology and Oncology | |||||||||||||||||||||
|
Related Pulmonary Fibrosis News Articles Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in Family, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md., with a lot on the go, juggling her son's baseball games and her daughter's horseback-riding lessons with numerous committee obligations, organizing women's activities at her local synagogue. Biomarkers identified for idiopathic pulmonary fibrosis The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science. UCSF marks a milestone with 500th transplant in heart and lung program UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung. Rare Lung Disease Cells Indicate Higher Death Risk Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, UC researchers have discovered. Smoking belies milder disease but worse prognosis for IPF patients Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London. Researchers show that fibrosis can be stopped, cured and reversed University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage. Molecular pathway appears crucial in development of pulmonary fibrosis A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment. Experts predict high mortality rates from pulmonary fibrosis will continue to rise Mortality rates from pulmonary fibrosis (PF) have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado. Scleroderma Outlook Improves as Survival Increases Individuals with scleroderma are living significantly longer today, compared with 30 years ago, and the physicians who treat this rare disease of connective tissue hope the newer drugs now on the market may extend lives even further. More Pulmonary Fibrosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||